F35H12.5 Antibody

Target Specificity

F35.25 is a monoclonal antibody (McAb) that binds specifically to the preS1 region of HBV surface antigen (HBsAg). The preS1 region spans amino acids 21–47 in HBV subtypes adw2 and ayw, with critical epitopes identified as P12–47 .

Mechanism of Action

F35.25 prevents HBV entry into hepatocytes by:

• Blocking receptor interaction: The preS1 region mediates HBV attachment to hepatocyte receptors. F35.25 competes with HBV for receptor binding .

• Inhibiting viral internalization: PreS1-specific antibodies disrupt viral uptake, reducing infection rates in in vitro models .

Potential Modifications

Challenges and Considerations

• Cross-reactivity: HBV-specific antibodies may show off-target binding to host tissues (e.g., actin, M2 protein), as observed in SARS-CoV-2 antibodies .

• Therapeutic Efficacy: Neutralizing antibodies like F35.25 require high-affinity binding to compete with viral attachment .

Research Gaps and Future Directions

1. Structural Elucidation: Crystallography or cryo-EM studies of F35.25 bound to preS1 would validate epitope mapping .

2. Clinical Translation: Testing F35.25 derivatives in HBV animal models to assess in vivo efficacy.

3. Biosimilar Development: Leveraging synthetic antibody libraries for cost-effective production of preS1-targeting clones .